Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.75 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896555 | 1.00 | SLC5A2 (0.75) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL13822945 | 0.87 | SLC5A2 (0.71) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL8628471 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL12714462 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL17772218 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL13468780 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL8587960 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL156012 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL22783104 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL6343834 | 0.84 | SLC5A2 (0.75) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099791-B1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-21 | — | — | EP | claimed |
| US-7666845-B2 | Compounds having inhibitory activity against sodium-dependent glucose transporter | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-23 | — | — | US | claimed |
| EP-2099791-A1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | Janssen Pharmaceutica, N.V. (BE) | 2009-09-16 | — | — | EP | claimed |
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | claimed |
| WO-2008070609-A1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | claimed |
| EP-2099791-B1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-21 | — | — | EP | disclosed |
| US-7666845-B2 | Compounds having inhibitory activity against sodium-dependent glucose transporter | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-23 | — | — | US | disclosed |
| EP-2099791-A1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | Janssen Pharmaceutica, N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| WO-2008070609-A1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ABCB11 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.